https://viavid.webcasts.com/starthere.jsp?ei=1677787&tp_key=b286b1a375 For those who cannot listen to the live broadcast, an online replay will be available in the Investors section of Inotiv's web site at: https://www.inotivco.com/investors/investor-information/. About Inotiv Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company's products and servi ...

"We are also pleased OBRC agreed to further extend the maturity date of the OBRC payable note. Inotiv will continue to evaluate opportunities to optimize our balance sheet. Inotiv acquired Orient BioResource Center's ("OBRC") primate quarantine and holding facility, located near Alice, Texas, in 2022. As part of the original purchase consideration, the Company agreed to leave in place a payable note owed by OBRC to the seller in the amount of $3.7 million. Originally, the payable note bore no interest and w ...

WEST LAFAYETTE, Ind., June 03, 2024 (GLOBE NEWSWIRE) -- Inotiv Inc. – Inotiv Inc. ("Inotiv" or the "Company") (Nasdaq: NOTV), a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models, today announced that it reached an agreement with the U.S. Department of Justice ("DOJ") to resolve a previously-announced criminal investigation into the shuttered canine breeding facility located in Cumberland, Virginia, which was o ...

Moving forward, the Company plans to continue to take important steps toward best-in-class animal welfare practices and a culture of compliance across its operations. Additional details about Inotiv's longstanding commitment to animal welfare and a timeline of the facts can be found at www.Inotivco.com/about/Cumberland. WEST LAFAYETTE, Ind., June 03, 2024 (GLOBE NEWSWIRE) -- Inotiv Inc. – Inotiv Inc. ("Inotiv" or the "Company") (Nasdaq: NOTV), a leading contract research organization dedicated to providing ...

About the Company Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company's products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Inotiv is committed to supporting discovery a ...

WEST LAFAYETTE, Ind., May 23, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in the upcoming 21st Annual Craig Hallum Institutional Investor Conference and Jefferies Globa ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from ___________ to _____________. Commission File Number 000-23357 INOTIV, INC. (Exact name of the registrant as specified in its charter) INDIA ...

Exhibit 99.1 Inotiv Reports Second Quarter Financial Results for Fiscal 2024 and Provides Business Update WEST LAFAYETTE, IN, May 15, 2024– Inotiv, Inc. (Nasdaq: NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q2 FY 2024") and six months ("YTD FY 2024") ended March 31, 2024. Revenue by Segment | (in ...

If you purchased Inotiv stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. atjkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/inotiv/ to discuss your legal rights. Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class ac ...

Core Points - Inotiv (NASDAQ:NOTV) reported preliminary results for Q1 2024, indicating a revenue of $254.5 million for the six months ending March 31, 2024, which is a 7.2% decrease from $274.2 million in the same period the previous year [1][2] - The decline in revenue is attributed to a $22.9 million decrease in Research Models and Services revenue, primarily due to lower non-human primate sales and the impact of selling its Israeli business in Q4 2023 [2] - Inotiv issued a warning to shareholders regarding the uncertainty of sales increases for the remainder of the 2024 fiscal year, indicating potential non-compliance with financial covenants if revenue and operating margins do not improve [3] - As of Tuesday morning, NOTV stock has decreased by 34.8%, with over 234,000 shares traded, which is below its daily average trading volume of approximately 497,000 shares [3]